Palleon un­veils PhI look at 'lawn mow­er' ap­proach to gly­coim­munol­o­gy: #AACR23

For more than 50 years, it’s been known that some pa­tients’ tu­mors have an abun­dance of sialo­gly­cans, com­plex car­bo­hy­drate chains at­tached to pro­teins and lipids, and those pa­tients tend to do a lot worse.

It was lat­er dis­cov­ered that the up­reg­u­la­tion of sialo­gly­cans sup­press­es the im­mune sys­tem in more than 50% of can­cer pa­tients, ac­cord­ing to Palleon Phar­ma­ceu­ti­cals. Led by re­search from No­bel lau­re­ate Car­olyn Bertozzi’s lab, the team at Palleon is now work­ing on a way to use gly­cans as a form of check­point ther­a­py – and they of­fered a look at their first-in-hu­man da­ta at this year’s Amer­i­can As­so­ci­a­tion for Can­cer Re­search Con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER